|
| Press Releases |
|
 |
|
| Wednesday, September 8, 2021 |
|
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药，一家专注于肿瘤治疗领域的创新型全球生物制药公司，今日宣布其口服泛PI3K抑制剂buparlisib（AN2025）、口服EP4拮抗剂（AN0025）与PD-L1抑制剂atezolizumab（阿替利珠单抗）三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。
more info >> |
|
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
| 阿諾醫藥，一家專注於腫瘤治療領域的創新型全球生物製藥公司，今日宣佈其口服泛PI3K抑制劑buparlisib（AN2025）、口服EP4拮抗劑（AN0025）與PD-L1抑制劑atezolizumab（阿替利珠單抗）三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
| Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
| Thursday, July 15, 2021 |
|
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
| Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Davos Highlights Physical AI as Key Trend, 51 WORLD (6651.HK) Emerges as Industry Implementer
Jan 22, 2026 20:13 HKT/SGT
|
|
|
Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 22, 2026 20:00 HKT/SGT
|
|
|
The 35th Education & Careers Expo opens today
Jan 22, 2026 19:00: JST
|
|
|
The 35th Education & Careers Expo opens today
Jan 22, 2026 18:00 HKT/SGT
|
|
|
向「數」而生 由「智」而行：中國數智科技全面開啟Web3.0全生態佈局
Jan 22, 2026 11:56 HKT/SGT
|
|
|
向"数"而生 由"智"而行：中国数智科技全面开启Web3.0全生态布局
Jan 22, 2026 11:56 HKT/SGT
|
|
|
龍旗科技今日登陸港交所：強大基石陣容 端側AI龍頭龍旗邁入全球化發展新紀元
Jan 22, 2026 11:38 HKT/SGT
|
|
|
龙旗科技今日登陆港交所：强大基石阵容 端侧AI龙头龙旗迈入全球化发展新纪元
Jan 22, 2026 11:38 HKT/SGT
|
|
|
みずほ銀行と富士通、受発注・決済領域における中堅・中小企業向け新サービス創出に向けた企画・開発を開始
Jan 22, 2026 11:30: JST
|
|
|
華營控股榮膺「香港義工獎2025」雙項殊榮 實踐企業責任 共建關愛香港
Jan 22, 2026 11:00 HKT/SGT
|
|
|
Fujitsu and Mizuho Bank partner to develop new order and payment processing service for SMEs
Jan 22, 2026 11:30 JST
|
|
|
AmplifiX Releases Comprehensive Sector Report on the Rapid Acceleration of Real-World Asset (RWA) Tokenization
Jan 21, 2026 23:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES to Exhibit Advanced Precious Metal Materials for Medical Device Components at MD&M West 2026
Jan 21, 2026 22:00 JST
|
|
|
mRNA腫瘤疫苗五年數據印證療效 雲頂新耀搶跑國內個性化腫瘤疫苗賽道
Jan 21, 2026 19:00 HKT/SGT
|
|
|
mRNA肿瘤疫苗五年数据印证疗效 云顶新耀抢跑国内个性化肿瘤疫苗赛道
Jan 21, 2026 19:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
